As global demand for biologics rises, pharmaceutical manufacturing is undergoing a structural shift. Biologic drugs, including monoclonal antibodies, vaccines, and advanced therapies, are expected to account for nearly 35–40 percent of the global pharmaceuticals market by 2030, according to IQVIA. At the same time, rising costs in the United States and Europe, along with supply disruptions during the Covid-19 pandemic, have accelerated the need for more diversified and resilient manufacturing ecosystems.

India is emerging as part of this transition. Known for supplying over 20 percent of the world’s generic medicines by volume, & being the vaccine hub, the country is now expanding into more complex biologics manufacturing, supported by improving technical capabilities and cost advantages.